BioCentury
ARTICLE | Company News

Pfizer, InnoPharma deal

July 21, 2014 7:00 AM UTC

Pfizer will acquire sterile injectable company InnoPharma for $225 million in cash up front. InnoPharma is also eligible for up to $135 million in milestones. InnoPharma develops sterile injectable formulations of generic drugs, and its portfolio includes 10 products approved in the U.S. and 19 products under FDA review. Pfizer said the acquisition will bolster its sterile injectables portfolio to 73 products. The company’s injectables portfolio is part of its Global Established Pharma business. The InnoPharma deal is expected to close this quarter. Kaye Scholer LLP acted as legal advisor to Pfizer. JPMorgan was financial advisor and Morgan, Lewis & Bockius LLP was legal advisor to InnoPharma. ...